BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Expected to Post Quarterly Sales of $50.59 Million

Equities research analysts expect BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRXGet Rating) to post $50.59 million in sales for the current quarter, according to Zacks. Five analysts have made estimates for BioCryst Pharmaceuticals’ earnings. The highest sales estimate is $55.47 million and the lowest is $47.10 million. BioCryst Pharmaceuticals reported sales of $19.06 million in the same quarter last year, which indicates a positive year-over-year growth rate of 165.4%. The company is expected to issue its next quarterly earnings results before the market opens on Monday, January 1st.

On average, analysts expect that BioCryst Pharmaceuticals will report full-year sales of $268.91 million for the current financial year, with estimates ranging from $261.18 million to $278.91 million. For the next year, analysts expect that the firm will report sales of $379.63 million, with estimates ranging from $348.06 million to $429.32 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for BioCryst Pharmaceuticals.

BioCryst Pharmaceuticals (NASDAQ:BCRXGet Rating) last announced its quarterly earnings results on Wednesday, February 23rd. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.09). The business had revenue of $47.16 million for the quarter, compared to the consensus estimate of $48.18 million.

BCRX has been the subject of several recent research reports. Zacks Investment Research upgraded shares of BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, April 13th. Bank of America lowered shares of BioCryst Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $21.00 to $14.00 in a research note on Monday, April 11th. Barclays cut BioCryst Pharmaceuticals from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $22.00 to $13.00 in a research note on Monday, April 18th. Royal Bank of Canada dropped their price target on BioCryst Pharmaceuticals from $16.00 to $14.00 and set a “sector perform” rating on the stock in a report on Tuesday, April 12th. Finally, HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Thursday, February 24th. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $19.09.

NASDAQ BCRX traded down $0.38 during trading hours on Monday, hitting $9.29. The company had a trading volume of 4,747,773 shares, compared to its average volume of 6,670,730. The firm’s 50 day moving average is $14.62 and its 200 day moving average is $14.29. The company has a market capitalization of $1.72 billion, a price-to-earnings ratio of -9.02 and a beta of 2.34. BioCryst Pharmaceuticals has a fifty-two week low of $9.25 and a fifty-two week high of $19.99.

In related news, Director George B. Abercrombie sold 5,000 shares of the stock in a transaction that occurred on Tuesday, February 15th. The stock was sold at an average price of $18.50, for a total transaction of $92,500.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Helen M. Thackray sold 7,600 shares of the firm’s stock in a transaction dated Friday, April 1st. The shares were sold at an average price of $16.20, for a total transaction of $123,120.00. Following the completion of the sale, the insider now owns 136,400 shares of the company’s stock, valued at approximately $2,209,680. The disclosure for this sale can be found here. Corporate insiders own 4.80% of the company’s stock.

Large investors have recently bought and sold shares of the business. Hanseatic Management Services Inc. bought a new position in BioCryst Pharmaceuticals in the first quarter valued at approximately $91,000. DekaBank Deutsche Girozentrale raised its holdings in shares of BioCryst Pharmaceuticals by 10.0% during the first quarter. DekaBank Deutsche Girozentrale now owns 73,765 shares of the biotechnology company’s stock worth $1,213,000 after acquiring an additional 6,700 shares during the period. Assenagon Asset Management S.A. lifted its position in BioCryst Pharmaceuticals by 435.2% in the 1st quarter. Assenagon Asset Management S.A. now owns 70,844 shares of the biotechnology company’s stock valued at $1,152,000 after acquiring an additional 57,608 shares in the last quarter. Strs Ohio acquired a new position in BioCryst Pharmaceuticals in the 1st quarter worth $32,000. Finally, First Hawaiian Bank increased its holdings in BioCryst Pharmaceuticals by 68.2% during the 1st quarter. First Hawaiian Bank now owns 51,735 shares of the biotechnology company’s stock worth $841,000 after purchasing an additional 20,970 shares in the last quarter. 57.08% of the stock is owned by hedge funds and other institutional investors.

About BioCryst Pharmaceuticals (Get Rating)

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

Further Reading

Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with's FREE daily email newsletter.